Treatment

Mood stabilizers

Medically reviewed by the Shrinkopedia editorial team, led by Shariq Refai, MD, MBA.

8 min read · 1,693 words

Medically reviewed . Reviewed by a board-certified psychiatrist before publication.
Sourced from primary literature . DSM-5-TR, NICE, the American Psychiatric Association, the NIMH, Cochrane, peer-reviewed research.
Dated and kept current . Every entry shows when it was published, reviewed, and last updated.
Honest about uncertainty . Each entry carries an evidence-strength rating and a "what we know and what we don't" section.
Independent . No advertising, no affiliate revenue, no sponsored content.

Quick answer

Mood stabilizers are a class of medications used mainly to treat bipolar disorder. They help control episodes of mania and depression and help prevent future episodes. Lithium is the classic mood stabilizer, with strong, long-standing evidence. These medications treat and prevent episodes rather than cure the condition, they're usually taken long-term, and they're managed closely with a prescriber.

Prefer the quick definition? Read this term on Shrinktionary →

Definition

Mood stabilizers are medications used to steady mood over time, mainly in bipolar disorder. Their job is twofold: to help bring an active episode of mania or depression under control, and, taken on an ongoing basis, to reduce how often and how severely future episodes occur.

The classic mood stabilizer is lithium, which has strong, long-standing evidence behind it, including evidence that it reduces suicide risk in bipolar disorder. Other medications used as mood stabilizers include certain anticonvulsants, such as valproate and lamotrigine. In practice, some atypical antipsychotics also serve a mood-stabilizing role and are used in bipolar disorder, sometimes alongside a mood stabilizer.

This entry is an overview. Drug-by-drug detail and anything to do with dosing belongs with a prescriber and with a dedicated medication resource such as PsychiatryRx.org.

### Mood stabilizers at a glance

Agent	Best-supported phase	Typical dose	Serum monitoring	Notable features
lithium	mania, maintenance, suicide prevention	600-1200 mg (level-guided)	0.6-1.2 mEq/L (draw 12 hrs post-dose); TSH, creatinine baseline and 6-12 monthly	strongest suicide-reduction evidence in psychiatry; narrow therapeutic index; renal and thyroid effects
valproate	mania, mixed states	750-2000 mg (level-guided)	50-125 mcg/mL trough	teratogenic (neural tube defects, cognitive effects); LFTs, CBC monitoring
lamotrigine	bipolar depression, maintenance	25 mg start → 200 mg	not routinely monitored	slow titration required (Stevens-Johnson risk); minimal weight/cognitive effects
carbamazepine	mania (second-line)	400-1600 mg (level-guided)	4-12 mcg/mL	strong CYP3A4 inducer (many drug interactions); auto-induction; monitor for agranulocytosis
oxcarbazepine	bipolar (limited evidence)	600-2400 mg	not routinely monitored	fewer drug interactions than carbamazepine; hyponatremia risk

What it looks like

A prescriber and a person work together to bring a manic or depressive episode under control.
Once things are steadier, the medication continues to lower the chance of the next episode.
For someone on lithium, periodic blood tests become a routine part of care.
Over time, the focus shifts from crisis to maintenance: fewer episodes, more stability.

What people often confuse this with

A cure for bipolar disorder. Mood stabilizers treat and prevent episodes; they don't cure the condition. That's why they're usually continued long-term in bipolar disorder, even when a person feels well, because the stability depends on staying on them.

Antidepressants. Mood stabilizers and antidepressants are different classes with different jobs. In bipolar disorder, antidepressants are used cautiously and usually not on their own, because of the risk of triggering mania. Mood stabilizers are the foundation of bipolar treatment.

Sedatives or "just calming pills." Mood stabilizers aren't simply calming agents. They act on the underlying instability of mood over time. Steadying mania and depression is a different effect from short-term sedation.

Reality check

Myth: Once I feel stable, I can stop my mood stabilizer.

The stability is, in large part, the medication working. In bipolar disorder, mood stabilizers are usually continued long-term, and stopping, especially stopping suddenly, carries a real risk of relapse. Any change belongs in a planned conversation with a prescriber.

Myth: The blood tests for lithium mean lithium is dangerous.

The monitoring isn't a sign that lithium is unsafe. It's how lithium is used safely. Regular blood tests keep the level in the range where it works well and is well tolerated, and they keep an eye on the thyroid and kidneys. The point is careful management, not alarm.

Myth: All mood stabilizers are interchangeable.

They're not. Lithium, valproate, lamotrigine, and others differ in what they treat best and in their safety considerations. Valproate carries specific risks in pregnancy and is generally avoided in people who could become pregnant. Lamotrigine needs slow dose increases because of a rare but serious rash. Which medication fits is a decision for a prescriber.

What research says

Mood stabilizers, lithium in particular, have a strong evidence base in bipolar disorder, supported by randomized controlled trials and reflected in clinical practice guidelines from bodies such as the American Psychiatric Association and NICE. Lithium has long-standing evidence both for treating acute episodes and for preventing future ones, and research also supports its role in reducing suicide risk in bipolar disorder. Anticonvulsants such as valproate and lamotrigine are established options, with lamotrigine particularly used for the depressive side of bipolar disorder, and atypical antipsychotics have evidence in bipolar disorder as well.

The practical realities are managed, not alarming. Lithium requires regular blood tests to keep its level safe and effective and to monitor the thyroid and kidneys. Valproate carries specific risks in pregnancy and is generally avoided in people who could become pregnant. Lamotrigine needs slow, careful dose increases because of a rare serious rash. These are reasons these medications are managed closely with a prescriber, who weighs the benefits and risks for each person. The choice of medication, and any change to it, belongs with that prescriber.

What we know and what we don't know

What we know

Mood stabilizers, especially lithium, are effective for treating and preventing episodes in bipolar disorder.
Lithium has strong evidence, including for reducing suicide risk in bipolar disorder.
They treat and prevent rather than cure, are usually long-term, and need close management with a prescriber.

What we don't know

Exactly how lithium produces its mood-stabilizing effect isn't fully understood.
Predicting in advance which person will respond best to which mood stabilizer isn't yet precise.
The long-term course differs from person to person, and treatment is adjusted over time with a prescriber.

What it involves

Treatment with a mood stabilizer usually involves:

a goal of controlling current episodes and preventing future ones
ongoing, often long-term use, because the protective effect depends on continuing the medication
regular contact with a prescriber to track mood, response, and side effects
for lithium specifically, regular blood tests to keep the level in a safe, effective range and to monitor the thyroid and kidneys
attention to specific safety points for particular medications, which a prescriber explains
not stopping suddenly, because abrupt discontinuation carries real risk

Medications in this class

Lithium

Receptor mechanism. Not a receptor drug; inhibits inositol monophosphatase, glycogen synthase kinase-3β (GSK-3β), and modulates second-messenger signaling. Robust anti-suicide effect (unique among mood stabilizers).

Typical dosing. 300 mg BID-TID starting; titrate to serum level.

Acute mania target: 1.0-1.2 mEq/L (up to 1.5 mEq/L)
Maintenance target: 0.6-0.8 mEq/L (up to 1.0 mEq/L)
Elderly: 0.4-0.8 mEq/L

Safety monitoring.

Serum lithium level 12 h post-dose: 5-7 days after start and each dose change; every 3 months once stable (every 6 months if very stable long-term).
Renal function (creatinine, eGFR): baseline, 3 months, then every 6-12 months.
Thyroid (TSH ± free T4): baseline, 3 months, then every 6-12 months.
Calcium/PTH: baseline and annually (hyperparathyroidism/hypercalcemia).
ECG at baseline in patients > 40 or with cardiac risk.
Weight, BMI, urinalysis; hCG in reproductive-age patients (Ebstein anomaly risk).
Toxicity. Levels > 1.5 mEq/L → tremor, GI symptoms, ataxia. > 2.0 mEq/L → confusion, seizures, a medical emergency. NSAIDs, ACE inhibitors, ARBs, thiazides, dehydration all raise level.

Sources. FDA label; NICE CG185 (bipolar disorder); International Society for Bipolar Disorders (ISBD) lithium consensus; Malhi et al., RANZCP 2020 mood disorder CPG.

Valproate (divalproex sodium, valproic acid)

Receptor mechanism. Increases GABA; blocks voltage-gated sodium channels; inhibits histone deacetylases.

Typical dosing. 15-20 mg/kg/day starting, divided; titrate to serum level 50-125 μg/mL for bipolar mania (higher end 80-125 μg/mL often needed).

Safety monitoring. Serum level trough at 3-5 days, with dose change, and periodically; CBC and LFTs baseline, month 1, then every 6 months; ammonia if mental status change; weight; menstrual/reproductive history (PCOS, hyperandrogenism); platelets. Contraindicated in pregnancy (neural tube defects, IQ reduction); avoid in reproductive-age patients without highly effective contraception.

Sources. FDA label (Depakote); NICE CG185; MHRA/FDA pregnancy safety communications; ISBD.

Carbamazepine

Receptor mechanism. Voltage-gated sodium channel blockade.

Typical dosing. 200 mg BID starting, titrate to 400-1600 mg/day divided; serum level 4-12 μg/mL.

Safety monitoring. CBC (aplastic anemia/agranulocytosis rare but serious), LFTs, sodium (SIADH → hyponatremia) baseline and periodically; serum level; HLA-B*1502 screening in patients of Asian ancestry (Stevens-Johnson syndrome risk); many CYP interactions (self-induces metabolism, so levels fall over first 4-6 weeks).

Sources. FDA label (Tegretol); FDA HLA-B*1502 boxed warning; NICE CG185.

Lamotrigine

Receptor mechanism. Voltage-gated sodium channel modulation; reduces glutamate release.

Typical dosing. Bipolar maintenance (depression prevention) requires slow titration: 25 mg/day × 2 weeks → 50 mg/day × 2 weeks → 100 mg/day × 1 week → 200 mg/day. Slower with valproate (starts 25 mg every other day). Faster titration → serious rash (Stevens-Johnson/TEN) risk.

Safety monitoring. Rash surveillance in weeks 2-8 (any rash → stop and reassess); no routine level; CBC, LFTs at baseline; slow re-titration required if > 5 half-lives missed.

Sources. FDA label (Lamictal, boxed warning); NICE CG185.

Oxcarbazepine

Receptor mechanism. Sodium channel blockade (like carbamazepine but no epoxide metabolite).

Typical dosing. 300 mg BID starting, up to 1200-2400 mg/day.

Safety monitoring. Sodium (higher hyponatremia risk than carbamazepine), CBC; less rigorous than carbamazepine; no strong bipolar efficacy evidence, so it is off-label for bipolar.

Sources. FDA label (Trileptal); NICE CG185.

Shared safety themes.

Pregnancy and breastfeeding. Every entry should link to condition-specific perinatal considerations and reference LactMed/NICE/APA perinatal guidance.
Drug interactions. SSRIs/SNRIs + MAOIs (14-day washout, 5 weeks for fluoxetine); lithium + NSAIDs/ACEi/thiazides; carbamazepine broad CYP induction; clozapine + fluvoxamine, ciprofloxacin.
Discontinuation. Taper SSRIs, SNRIs, benzodiazepines, and antipsychotics gradually. Fastest tapers (paroxetine, venlafaxine, short-acting benzos) carry the most discontinuation symptoms.
Metabolic monitoring standard. Per the ADA/APA consensus, still the standard framework in 2026: baseline, 4, 8, 12 weeks, then quarterly: weight/BMI, waist. Baseline, 3 months, then annually: fasting glucose or HbA1c, fasting lipids, BP.
QTc considerations. Baseline ECG for citalopram > 20 mg (age > 60), ziprasidone, IV haloperidol, thioridazine, and any combination of QT-prolonging agents.

Sources

American Psychiatric Association (APA). Practice guidelines for bipolar disorder.
National Institute for Health and Care Excellence (NICE). Guidance on bipolar disorder.
National Institute of Mental Health (NIMH). Bipolar Disorder and Mental Health Medications overviews.
U.S. Food and Drug Administration (FDA). Prescribing information for mood-stabilizing medications.
FDA prescribing information (label) for each drug, accessed via DailyMed.
APA Practice Guidelines (Schizophrenia 3rd ed.; MDD; Bipolar Disorder; OCD).
NICE Guidelines: NG222 (Depression 2022), CG185 (Bipolar 2014, updated), CG178 (Psychosis and schizophrenia 2014, updated), NG215 (Medicines associated with dependence).
ADA/APA Consensus on Antipsychotic Drugs and Obesity/Diabetes (2004, still foundational; updates via ISBD/EPA metabolic monitoring statements).
Carolan A, et al. Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation. Schizophrenia Bulletin. 2025;51(5):1193-1203.
FDA Drug Safety Communication: Clozapine REMS elimination (February 24, 2025).
AAPP Clozapine in Practice guideline (2025 updates).
International Society for Bipolar Disorders (ISBD) lithium and mood-stabilizer consensus statements.
APA/ASKP Consensus on Ketamine and Esketamine (2017 base; 2023-2025 updates).
Beers Criteria (AGS 2023) and STOPP/START v3 (2023) for prescribing in older adults.
Cochrane systematic reviews for individual class efficacy and safety.

Read how Shrinkopedia builds and reviews its content.

How to cite this page

Short: Mood stabilizers. Shrinkopedia, medically reviewed by Shariq Refai, MD, MBA. https://shrinkopedia.com/treatments/mood-stabilizers/
APA: Shrinkopedia. (2026, June 8). Mood stabilizers. Medically reviewed by Shariq Refai, MD, MBA. https://shrinkopedia.com/treatments/mood-stabilizers/
MLA: "Mood stabilizers." Shrinkopedia, 8 June 2026, https://shrinkopedia.com/treatments/mood-stabilizers/.

Click a citation to select it.

Medical disclaimer

Shrinkopedia is for education, not medical advice. It can't tell you whether a mood stabilizer is right for you, and it isn't a substitute for care from a licensed clinician. Decisions about these medications, including starting, changing, or stopping one, belong with a prescriber who knows your situation.

If you're in crisis or thinking about harming yourself, call or text 988 in the US to reach the Suicide and Crisis Lifeline, or call 911.

See where this fits in the Atlas: how your mind works →

The Knowledge Path

Walk the connection from this entry outward.

1 TREATMENT Mood stabilizers (current)
2 CONDITION Bipolar I vs bipolar II
3 SYMPTOM Racing thoughts
4 MEDICATION Mood stabilizers explained
5 CARE Bipolar I care at shrinkMD

The Knowledge Path is a curated walk. Every step is one decision away from the next.

Your next step in The Shrink Network

You are here: Shrinkopedia, the concept layer of The Shrink Network.

Understand the idea here first, then follow it to the property that takes it further.

Read a related treatment →

Want to understand more first?

Disclosure: shrinkMD is the clinical care practice within The Shrink Network, the same network that publishes Shrinkopedia. Shrinkopedia takes no referral or affiliate commission for care.